13.1 Oncology Nutrition & Cancer Cachexia

13.1 Oncology Nutrition & Cancer Cachexia

Clinical Core: Cancer cachexia is an involuntary, cytokine-driven metabolic syndrome defined by progressive skeletal muscle wasting—with or without adipose tissue loss—that cannot be reversed by conventional nutritional support alone. Driven by pro-inflammatory cytokines ($\text{TNF}-\alpha$, $\text{IL}-1$, $\text{IL}-6$, $\text{IFN}-\gamma$) and tumor-derived catabolic peptides like Proteolysis-Inducing Factor (PIF), cachexia induces systemic hypercatabolism, futile substrate cycling, and anorexia. Clinical management requires precise staging under international consensus guidelines: while proactive enteral access (such as prophylactic gastrostomy) prevents treatment interruptions and protects pharyngeal musculature in head and neck radiation, terminal refractory cachexia ($ECOG\text{ }3\text{--}4$, survival $< 3\text{ months}$) dictates a shift to palliative comfort care where aggressive artificial feeding is contraindicated.

---

Metabolic Alterations & Pathophysiology of Cancer Cachexia

Cancer cachexia represents a fundamental breakdown of normal metabolic homeostasis. Unlike simple starvation, where the body adapts to conserve lean tissue, cancer cachexia is characterized by an unconstrained, systemic pro-inflammatory and hypercatabolic state.

+-----------------------------------------------------------------------------------------+
|                        SIMPLE STARVATION vs. CANCER CACHEXIA                            |
+-----------------------------------------------------------------------------------------+
| Characteristic        | Simple Starvation               | Cancer Cachexia               |
| --------------------- | ------------------------------- | ----------------------------- |
| Primary Fuel Source   | Fatty acids, Ketone bodies      | Glucose, Amino acids, Lipids  |
| Muscle Proteolysis    | Decreased (spared)              | Marked, persistent breakdown  |
| Systemic Inflammation | Absent / Minimal                | Intense (TNF, IL-6, CRP)      |
| Resting Energy Exp.   | Decreased (hypometabolic)       | Variable / Often elevated     |
| Insulin Sensitivity   | Normal or slightly decreased    | Severe insulin resistance     |
| Nutritional Reversal  | Fully reversed by feeding       | Incompletely / poorly reversed|
+-----------------------------------------------------------------------------------------+

1. The Pro-Inflammatory Cytokine Cascade

Host immune cells (macrophages, monocytes, lymphocytes) and malignant tumor cells secrete pro-inflammatory cytokines that orchestrate widespread systemic catabolism:

• Tumor Necrosis Factor-alpha ($\text{TNF}-\alpha$, Cachectin): Stimulates skeletal muscle protein degradation via nuclear factor kappa B ($\text{NF}-\kappa\text{B}$) signaling, suppresses lipoprotein lipase (LPL) activity (leading to hypertriglyceridemia and impaired lipid clearance), accelerates adipocyte lipolysis, and acts on hypothalamic satiety centers to induce severe anorexia.
• Interleukin-6 ($IL\text{-}6$): The primary driver of the hepatic acute-phase response, stimulating C-reactive protein (CRP) and fibrinogen synthesis while downregulating albumin production. Serum $IL\text{-}6$ levels correlate directly with the magnitude of muscle mass loss, functional decline, and reduced survival.
• Interleukin-1 ($\text{IL}-1$) & Interferon-gamma ($\text{IFN}-\gamma$): Synergize with $\text{TNF}-\alpha$ and $\text{IL}-6$ to amplify proteolysis, suppress gastric motility, and blunts central orexigenic appetite signals.

2. Tumor-Specific Catabolic Mediators

In addition to host cytokines, specialized circulating factors produced directly by cancer cells accelerate tissue wasting:

• Proteolysis-Inducing Factor (PIF): A $24\text{ kDa}$ sulfated glycoprotein isolated from cachexia-inducing tumors. PIF binds to specific surface receptors on skeletal muscle, activating the intracellular ATP-dependent ubiquitin-proteasome pathway. It upregulates the expression of the $20S$ proteasome core and key ubiquitin ligases (MuRF1 and MAFbx/atrogin-1), accelerating the degradation of myofibrillar proteins (actin and myosin). Concurrently, PIF inhibits eukaryotic translation initiation factor 2 ($eIF2\alpha$), suppressing new protein synthesis.
• Lipid-Mobilizing Factor (LMF) / Zinc-$\alpha_2$-Glycoprotein (ZAG): Acts directly on adipocyte $\beta_3$-adrenergic receptors to stimulate adenylate cyclase, elevating intracellular cyclic AMP (cAMP) and activating hormone-sensitive lipase (HSL). This drives uninhibited lipolysis, releasing vast quantities of free fatty acids and glycerol into the circulation.

3. Futile Substrate Cycling & Neuroendocrine Derangements

• Cori Cycle Hyperactivity: Anaerobic glycolysis within poorly vascularized tumor cells converts glucose to lactate. This lactate enters the systemic circulation and travels to the liver, where hepatic gluconeogenesis converts 2 lactate molecules back into 1 glucose molecule at the cost of 6 ATP. Because tumor glycolysis yields only 2 ATP per glucose, this futile cycle consumes a net of 4 ATP per cycle, wasting up to $300\text{ kcal/day}$ of energy.
• Mitochondrial Uncoupling: Cytokines upregulate uncoupling proteins ($UCP\text{-}1$, $UCP\text{-}2$, $UCP\text{-}3$) in brown and white adipose tissue and skeletal muscle. These proteins dissipate the mitochondrial proton gradient as heat instead of capturing it as ATP, inducing inefficient energy utilization and non-shivering thermogenesis.
• Hypothalamic Appetite Suppression: Circulating cytokines cross the blood-brain barrier at the arcuate nucleus, inhibiting orexigenic neurons (Neuropeptide Y [NPY] and Agouti-Related Peptide [AgRP]) while stimulating anorexigenic neurons (Pro-opiomelanocortin [POMC] and Cocaine- and Amphetamine-Regulated Transcript [CART]), producing profound central anorexia.

---

International Consensus Staging of Cancer Cachexia

Under the international consensus framework established by Fearon et al. (Lancet Oncology, 2011), cancer cachexia is recognized as a continuous spectrum encompassing three distinct clinical stages:

+-----------------------------------------------------------------------------------------+
|                        STAGES OF CANCER CACHEXIA (Fearon et al.)                        |
+-----------------------------------------------------------------------------------------+
| Stage                 | Diagnostic Criteria             | Clinical & Metabolic Features |
| --------------------- | ------------------------------- | ----------------------------- |
| 1. Precachexia        | Weight loss <= 5% in 6 months   | Anorexia, impaired glucose    |
|                       | with systemic inflammation      | tolerance, elevated CRP       |
| --------------------- | ------------------------------- | ----------------------------- |
| 2. Cachexia           | Weight loss > 5% in 6 months, OR| Ongoing muscle wasting, loss  |
|                       | BMI < 20 with weight loss > 2%, | of adipose tissue, systemic   |
|                       | OR sarcopenia with wt loss > 2% | inflammation, reduced intake  |
| --------------------- | ------------------------------- | ----------------------------- |
| 3. Refractory         | Pro-catabolic, unresponsive to  | ECOG 3-4, expected survival   |
|    Cachexia           | antineoplastic therapy          | < 3 months; palliative focus  |
+-----------------------------------------------------------------------------------------+

1. Precachexia

Patients exhibit modest involuntary weight loss ($\le 5\%$ of stable body weight over the preceding 6 months), accompanied by early metabolic and inflammatory changes (elevated CRP, altered glucose tolerance) and anorexia. Muscle loss may be undetectable on physical exam but can be identified on cross-sectional CT imaging. This stage represents the optimal window for early nutritional intervention and multimodal anti-inflammatory therapies.

2. Cachexia

Diagnosed when patients meet any of the following criteria in the absence of simple starvation:

1. Weight loss $> 5\%$ over the past 6 months;
2. BMI $< 20\text{ kg/m}^2$ and ongoing weight loss $> 2\%$;
3. Confirmed sarcopenia (reduced skeletal muscle index via CT at L3 or DXA) and ongoing weight loss $> 2\%$. Patients typically experience reduced food intake ($< 1500\text{ kcal/day}$ or $< 75\%$ of normal requirements), systemic inflammation, and functional impairment. Multimodal therapy combining targeted nutritional support, resistance exercise, and anti-inflammatory strategies is indicated to stabilize lean mass.

3. Refractory Cachexia

Characterized by advanced cancer that is progressive and unresponsive to antineoplastic therapy, active systemic catabolism, profound muscle wasting, poor performance status (Eastern Cooperative Oncology Group [ECOG] score 3 or 4; Karnofsky Performance Scale $< 50\%$), and an anticipated life expectancy of less than 3 months.

Palliative Shift in Refractory Cachexia: In refractory cachexia, aggressive artificial nutrition (enteral tube feeding or total parenteral nutrition) cannot reverse muscle wasting or improve survival. Instead, aggressive feeding induces fluid overload, pulmonary secretions, peripheral edema, ascites, and gastrointestinal distress. Management shifts entirely to palliative comfort: managing thirst with oral swabs, ice chips, and small sips of favorite foods for pleasure, alleviating nausea, and providing emotional support to the patient and family.

---

Head & Neck Cancers & Radiation Toxicity

Patients with head and neck squamous cell carcinoma (HNSCC) undergoing definitive radiation therapy (RT) or concurrent chemoradiotherapy (CRT) represent one of the highest-risk oncology populations for severe malnutrition.

Toxicities of Head and Neck Radiation

• Oral Mucositis: Cytotoxic damage to basal epithelial cells results in painful, confluent mucosal ulcerations (World Health Organization [WHO] Grade 3–4), creating excruciating odynophagia that prevents solid and liquid oral intake.
• Xerostomia: Ionizing radiation causes irreversible microvascular injury and acinar cell death in salivary glands. The loss of serous saliva causes profound oral dryness, loss of salivary enzymes, painful tongue fissures, and thick, ropy secretions that impair bolus formation and trigger gagging.
• Dysgeusia & Ageusia: Direct radiation injury to taste buds results in severe taste distortion, metallic taste perversion, or total loss of taste, eliminating the pleasure of eating.
• Radiation-Induced Trismus: Fibrosis of the masseter and pterygoid muscles leads to progressive reduction in maximal interincisal opening ($< 35\text{ mm}$), severely restricting food intake and oral hygiene.

Proactive / Prophylactic Gastrostomy Placement

Clinical practice guidelines strongly endorse proactive (prophylactic) gastrostomy (percutaneous endoscopic gastrostomy [PEG] or radiologically inserted gastrostomy [RIG]) prior to initiating definitive RT/CRT in high-risk patients:

• High-Risk Indications: Stage III or IV HNSCC, primary tumors of the base of tongue, tonsillar fossa, hypopharynx, or larynx; planned concurrent platinum-based chemotherapy; large bilateral neck radiation fields; baseline weight loss $> 5\%$; or anticipated severe mucositis.
• Proven Benefits: Proactive PEG placement prevents treatment interruptions (which directly reduce locoregional tumor control and cure rates), avoids severe dehydration, averts unplanned emergency admissions, and prevents catastrophic weight loss ($> 10\%$).

+-----------------------------------------------------------------------------------------+
|               HEAD & NECK CRT: THE "USE IT OR LOSE IT" SWALLOWING PRINCIPLE             |
+-----------------------------------------------------------------------------------------+
| Practice              | Physiological Mechanism         | Clinical Consequence          |
| --------------------- | ------------------------------- | ----------------------------- |
| Complete NPO          | Pharyngeal constrictor disuse   | Permanent pharyngeal fibrosis, |
| during tube feeding   | atrophy and scarring            | lifelong tube dependency      |
| --------------------- | ------------------------------- | ----------------------------- |
| Daily swallowing      | Active muscle fiber recruitment | Preservation of swallow reflex|
| exercises + oral sips | prevents fibrotic contracture   | successful tube weaning post-RT|
+-----------------------------------------------------------------------------------------+

• The Swallowing Preservation Imperative: Patients supported by gastrostomy must be enrolled in structured swallowing therapy and instructed to perform daily swallowing exercises and ingest small oral sips of water or liquids throughout radiotherapy. Allowing the patient to remain completely NPO induces rapid disuse atrophy and permanent fibrotic tethering of the pharyngeal constrictor muscles and suprahyoid complex, resulting in permanent dysphagia and lifelong tube dependency.

---

Radiation Enteritis: Acute vs. Chronic

Radiation to the abdomen or pelvis induces distinct acute and chronic intestinal pathologies with differing nutritional priorities.

• Acute Enteritis Management: Management is supportive. Mucosal denudation blunts brush-border enzymes, causing secondary lactase deficiency; a transient lactose-free diet is indicated. Soluble fiber (e.g., banana flakes, guar gum) promotes short-chain fatty acid production to nourish colonocytes, while loperamide controls transit time. Acute enteritis typically resolves within 2 to 6 weeks after radiation ceases.
• Chronic Enteritis Management: Chronic radiation enteritis is a progressive, irreversible ischemic pan-enteropathy. Dense collagen deposition and obliterative arteriopathy cause fixed mechanical strictures, bacterial overgrowth (SIBO), and radiation-induced intestinal failure. While peptide-based or semi-elemental EN can be attempted in non-obstructed segments, long-term Home Parenteral Nutrition (HPN) is the definitive life-sustaining therapy when severe short bowel syndrome, multiple strictures, or extensive fistulae preclude enteral absorption.

---

Specialized Nutrition Support & Pharmacotherapy

Enteral Nutrition (EN) vs. Parenteral Nutrition (PN)

• "If the Gut Works, Use It": Enteral nutrition is the preferred route whenever the gastrointestinal tract is functional and accessible. EN preserves gut-associated lymphoid tissue (GALT), maintains the secretory IgA barrier, prevents mucosal atrophy, blunts bacterial translocation, and carries substantially lower risks of catheter-related bloodstream infections (CRBSI) and metabolic derangements.
• Indications for EN: Indicated when oral intake is anticipated to be $< 60\%$ of estimated nutritional requirements for $> 7\text{--}10\text{ days}$ in adequately nourished patients, or $> 5\text{ days}$ in malnourished patients.
• Indications for PN: Total parenteral nutrition is strictly reserved for patients with severe gastrointestinal dysfunction where the gut cannot be utilized for $> 7\text{ days}$, including: complete mechanical bowel obstruction, severe prolonged paralytic ileus, high-output enterocutaneous fistulas where distal access is unavailable, severe gastrointestinal Graft-versus-Host Disease (GVHD) refractory to medical therapy, and chronic radiation-induced intestinal failure.
• Contraindication of Routine PN: Routine total parenteral nutrition administered to oncology patients undergoing chemotherapy or radiation who possess a functioning gastrointestinal tract is strictly contraindicated. Large randomized trials demonstrate that routine PN fails to improve tumor response or patient survival, but increases infectious morbidity threefold ($RR \approx 3.0$).

Neutropenic Precautions: Modern Evidence-Based Food Safety

For decades, immunocompromised oncology patients were subjected to restrictive "neutropenic diets" that prohibited fresh fruits, raw vegetables, and unpasteurized items. Extensive randomized controlled trials and Cochrane systematic reviews have conclusively demonstrated that restrictive neutropenic diets do not reduce infection rates or mortality compared to standard diets, while worsening anorexia, dietary variety, and quality of life.

• Current Guideline Standard: Implement rigorous food safety handling guidelines (FDA/USDA recommendations):
  1. Thorough hand washing and sanitizing of food preparation surfaces;
  2. Thoroughly washing all fresh fruits and vegetables under cold running water before peeling or consumption;
  3. Cooking meats, poultry, seafood, and eggs to certified safe internal temperatures (meat $\ge 160^\circ\text{F}$, poultry $\ge 165^\circ\text{F}$);
  4. Strict avoidance of raw or undercooked meats, unpasteurized dairy products, unpasteurized honey, raw sprouts, and deli meats unless heated to steaming hot;
  5. Preventing cross-contamination between raw meats and ready-to-eat foods; safe refrigerated storage at $< 40^\circ\text{F}$ ($< 4^\circ\text{C}$).

Appetite Stimulants (Orexigenic Pharmacotherapy)

+-----------------------------------------------------------------------------------------+
|                        APPETITE STIMULANTS IN CANCER CACHEXIA                           |
+-----------------------------------------------------------------------------------------+
| Medication            | Clinical Benefit                | Serious Risks & Limitations   |
| --------------------- | ------------------------------- | ----------------------------- |
| Megestrol Acetate     | Stimulates appetite; increases  | Venous thromboembolism (DVT); |
| (Synthetic Progestin) | weight (ADIPOSE & WATER ONLY,   | adrenal suppression/crisis;   |
|                       | no skeletal muscle gain)        | peripheral edema; hypogonadism|
| --------------------- | ------------------------------- | ----------------------------- |
| Corticosteroids       | Transient appetite boost,       | Tachyphylaxis at 2-4 weeks;   |
| (e.g., Dexamethasone) | antiemetic, improves fatigue    | steroid myopathy (worsens     |
|                       | and sense of well-being         | sarcopenia); hyperglycemia;   |
|                       |                                 | severe immunosuppression      |
+-----------------------------------------------------------------------------------------+

• Megestrol Acetate ($400\text{--}800\text{ mg/day}$): Stimulates central hypothalamic NPY release. While it increases appetite and caloric intake, body composition analyses confirm that weight gain consists almost entirely of adipose tissue and extracellular fluid retention, with zero accretion of lean skeletal muscle mass. Furthermore, it carries an elevated risk of deep vein thrombosis (DVT), pulmonary embolism, peripheral edema, hypogonadism, and secondary adrenal insufficiency due to intrinsic glucocorticoid activity.
• Corticosteroids (Dexamethasone $2\text{--}8\text{ mg/day}$): Provides rapid stimulation of appetite, reduces nausea, and improves sense of well-being. However, its efficacy is strictly limited by tachyphylaxis within 2 to 4 weeks. Long-term administration accelerates steroid-induced proximal muscle catabolism (directly worsening sarcopenia), induces secondary diabetes mellitus, suppresses immunity, and causes osteoporosis. Corticosteroids should be reserved exclusively for patients with advanced terminal disease and short life expectancy ($< 4\text{--}8\text{ weeks}$).